Thyroid hormone levels in Alzheimer disease : a systematic review and meta-analysis
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND AND OBJECTIVE: Thyroid hormone (TH) disturbances are perceived to contribute to cognitive impairment and dementia. However, there is no consensus on the association between TH levels and Alzheimer Disease (AD). In this study, we aimed to compare serum and cerebrospinal fluid (CSF) TH levels in AD patients to controls by performing a meta-analysis.
METHODS: We systematically searched online databases for papers comparing CSF or serum TH levels in AD patients to controls, and performed a meta-analysis on the extracted data.
RESULTS: Out of 1604 records identified, 32 studies were included. No significant difference in serum TSH (standardized mean difference (SMD): -0.03; 95% confidence interval (CI): -0.22-0.16), total T4 (SMD: 0.10; 95% CI: -0.29-0.49), and free T4 (SMD: 0.25; 95% CI: -0.16-0.69) levels were observed. However, there was significantly lower serum total T3 (SMD: -0.56; 95%CI: -0.97 to -0.15) and free T3 (SMD: -0.47; 95%CI: -0.89 to -0.05) levels in AD group compared to controls. Subgroup analyses on studies including only euthyroid patients did not show any significant difference in either of the thyroid hormone levels. Also, no significant difference in CSF total T4 and total T3/total T4 ratios but significantly lower CSF total T3 (SMD: -2.45; 95% CI: -4.89 to -0.02) in AD group were detected.
CONCLUSION: Serum total and free T3 and CSF total T3 levels are significantly lower in AD patients compared to controls. The temporality of changes in thyroid hormone levels and AD development should be illustrated by further longitudinal studies.
| Errataetall: |
CommentOn: Metab Brain Dis. 2021 Oct;36(7):1523-1543. - PMID 34146214 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Endocrine - 79(2023), 2 vom: 27. Feb., Seite 252-272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dolatshahi, Mahsa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
06LU7C9H1V |
|---|
| Anmerkungen: |
Date Completed 03.02.2023 Date Revised 04.04.2023 published: Print-Electronic CommentOn: Metab Brain Dis. 2021 Oct;36(7):1523-1543. - PMID 34146214 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12020-022-03190-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346817951 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346817951 | ||
| 003 | DE-627 | ||
| 005 | 20231226032346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12020-022-03190-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346817951 | ||
| 035 | |a (NLM)36166162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dolatshahi, Mahsa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thyroid hormone levels in Alzheimer disease |b a systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2023 | ||
| 500 | |a Date Revised 04.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Metab Brain Dis. 2021 Oct;36(7):1523-1543. - PMID 34146214 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: Thyroid hormone (TH) disturbances are perceived to contribute to cognitive impairment and dementia. However, there is no consensus on the association between TH levels and Alzheimer Disease (AD). In this study, we aimed to compare serum and cerebrospinal fluid (CSF) TH levels in AD patients to controls by performing a meta-analysis | ||
| 520 | |a METHODS: We systematically searched online databases for papers comparing CSF or serum TH levels in AD patients to controls, and performed a meta-analysis on the extracted data | ||
| 520 | |a RESULTS: Out of 1604 records identified, 32 studies were included. No significant difference in serum TSH (standardized mean difference (SMD): -0.03; 95% confidence interval (CI): -0.22-0.16), total T4 (SMD: 0.10; 95% CI: -0.29-0.49), and free T4 (SMD: 0.25; 95% CI: -0.16-0.69) levels were observed. However, there was significantly lower serum total T3 (SMD: -0.56; 95%CI: -0.97 to -0.15) and free T3 (SMD: -0.47; 95%CI: -0.89 to -0.05) levels in AD group compared to controls. Subgroup analyses on studies including only euthyroid patients did not show any significant difference in either of the thyroid hormone levels. Also, no significant difference in CSF total T4 and total T3/total T4 ratios but significantly lower CSF total T3 (SMD: -2.45; 95% CI: -4.89 to -0.02) in AD group were detected | ||
| 520 | |a CONCLUSION: Serum total and free T3 and CSF total T3 levels are significantly lower in AD patients compared to controls. The temporality of changes in thyroid hormone levels and AD development should be illustrated by further longitudinal studies | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Alzheimer disease | |
| 650 | 4 | |a Cerebrospinal fluid | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Serum | |
| 650 | 4 | |a Thyroid hormones | |
| 650 | 7 | |a Thyroid Hormones |2 NLM | |
| 650 | 7 | |a Triiodothyronine |2 NLM | |
| 650 | 7 | |a 06LU7C9H1V |2 NLM | |
| 650 | 7 | |a Thyroxine |2 NLM | |
| 650 | 7 | |a Q51BO43MG4 |2 NLM | |
| 700 | 1 | |a Salehipour, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Saghazadeh, Amene |e verfasserin |4 aut | |
| 700 | 1 | |a Sanjeari Moghaddam, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Aghamollaii, Vajiheh |e verfasserin |4 aut | |
| 700 | 1 | |a Fotouhi, Akbar |e verfasserin |4 aut | |
| 700 | 1 | |a Tafakhori, Abbas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine |d 1995 |g 79(2023), 2 vom: 27. Feb., Seite 252-272 |w (DE-627)NLM091795540 |x 1559-0100 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:2 |g day:27 |g month:02 |g pages:252-272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12020-022-03190-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 2 |b 27 |c 02 |h 252-272 | ||